Beam Accounts Payable from 2010 to 2024
| BEAM Stock | USD 23.58 0.91 3.72% |
Accounts Payable | First Reported 2018-12-31 | Previous Quarter 4.4 M | Current Value 3.8 M | Quarterly Volatility 2.6 M |
Check Beam Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Beam Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.7 M, Interest Expense of 49 M or Selling General Administrative of 122.7 M, as well as many indicators such as Price To Sales Ratio of 5.28, Dividend Yield of 0.0106 or PTB Ratio of 2.25. Beam financial statements analysis is a perfect complement when working with Beam Therapeutics Valuation or Volatility modules.
Beam | Accounts Payable |
Latest Beam Therapeutics' Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Beam Therapeutics over the last few years. An accounting item on the balance sheet that represents Beam Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Beam Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Beam Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Beam Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
Beam Accounts Payable Regression Statistics
| Arithmetic Mean | 3,131,677 | |
| Geometric Mean | 1,757,419 | |
| Coefficient Of Variation | 106.22 | |
| Mean Deviation | 2,980,749 | |
| Median | 726,000 | |
| Standard Deviation | 3,326,593 | |
| Sample Variance | 11.1T | |
| Range | 8.3M | |
| R-Value | 0.56 | |
| Mean Square Error | 8.1T | |
| R-Squared | 0.32 | |
| Significance | 0.03 | |
| Slope | 418,404 | |
| Total Sum of Squares | 154.9T |
Beam Accounts Payable History
About Beam Therapeutics Financial Statements
Beam Therapeutics investors utilize fundamental indicators, such as Accounts Payable, to predict how Beam Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 1.6 M | 1.5 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Beam Therapeutics Correlation against competitors. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share 4.273 | Quarterly Revenue Growth (0.17) | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.